Visugromab  (Synonyms: CTL-002)

Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003)^[1].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

GDF15

Visugromab (up to 100 mg/kg; per week) shows no toxicity in the pre-clinical toxicology test of cynomolgus monkeys^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

9518  [NCBI]

Q99988

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.56 kDa

2556646-63-8

Liquid

Colorless to light yellow

[Visugromab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Immobilized GDF-15 Protein, Human (P.pastoris, His, HY-P75170) can bind Visugromab. The EC₅₀ for this effect is 5.159 ng/mL.
• 
  Flow cytometric analysis of 1X10⁶ HeLa cells with Visugromab (HY-P99100, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control.

• [1]. Necchi A, et al. Neutralizing GDF-15 in muscle-invasive bladder cancer (MIBC): A neoadjuvant immunotherapy trial of visugromab (CTL-002) in combination with the anti-PD1 antibody nivolumab (NEO-GDFATHER)[J]. 2023.

  [2]. Melero I, et al. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature. 2025 Jan;637(8048):1218-1227.  [Content Brief]